C12N 2501/415
Wnt
Official title: Wnt; Frizzeled
C12N2501/415 (Wnt) appears on 700 US grants and 1,572 published applications in this corpus.
Search patents in C12N- Granted patents
- 700
- Published applications
- 1,572
- Assignees
- 513
- Inventors
- 2,511
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 2 | 2 |
| 2003 | 0 | 0 |
| 2004 | 0 | 10 |
| 2005 | 1 | 9 |
| 2006 | 1 | 18 |
| 2007 | 2 | 14 |
| 2008 | 2 | 15 |
| 2009 | 12 | 29 |
| 2010 | 7 | 37 |
| 2011 | 7 | 28 |
| 2012 | 12 | 33 |
| 2013 | 10 | 44 |
| 2014 | 23 | 50 |
| 2015 | 29 | 69 |
| 2016 | 30 | 93 |
| 2017 | 46 | 77 |
| 2018 | 49 | 84 |
| 2019 | 61 | 93 |
| 2020 | 52 | 114 |
| 2021 | 51 | 114 |
| 2022 | 55 | 137 |
| 2023 | 46 | 126 |
| 2024 | 73 | 136 |
| 2025 | 74 | 136 |
| 2026 | 52 | 104 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Haematopoietic stem/progenitor cells29 Sep 2026US 12,747,424 B2Murdoch Childrens Research Institute
- Method for obtaining healthy intestinal organoids22 Sep 2026US 12,741,061 B2Precision Cancer Technologies Inc.
- Pluripotent stem cell-derived heart organoid22 Sep 2026US 12,742,157 B2Board of Trustees of Michigan State University
- Generating aorta-gonad-mesonephros-like hematopoietic cells from human pluripotent stem cells under a defined condition15 Sep 2026US 12,735,679 B2Purdue Research Foundation
- Methods and compositions for generating oligodendrocyte progenitor cells8 Sep 2026US 12,729,368 B2Trailhead Biosystems Inc.
- Micropattern-assisted generation of tissue8 Oct 2026US 2026/0308533 A1
- Cryopreserved endocrine cells that express chromogranin a1 Oct 2026US 2026/0294981 A1ViaCyte, Inc.
- Cells, islets, and organoids that evade immune detection and autoimmunity, methods of production and use thereof1 Oct 2026US 2026/0297530 A1The Salk Institute for Biological Studies
- Oct3/4 protein variants, and method for producing induced pluripotent stem cells1 Oct 2026US 2026/0297535 A1Riken
- Reprogramming methods and cell culture platforms1 Oct 2026US 2026/0297537 A1Fate Therapeutics, Inc.
Most cited
By later US patents
- Definitive endoderm221US 7,510,876 B2Cythera, Inc. · 2009
- Targeted RNA degradation using nuclear antisense RNA207US 5,908,779 AUniversity of Connecticut · 1999
- Method for generating an animal homozygous for a genetic modification199US 7,294,754 B2Regeneron Pharmaceuticals, Inc. · 2007
- Methods of producing pancreatic hormones165US 7,534,608 B2Cythera, Inc. · 2009
- Methods for identifying factors for differentiating definitive endoderm163US 7,541,185 B2Cythera, Inc. · 2009